GMAB | tickerfilter.com

Fundamental analysis

34%

Profitability 49%

Dept financing 2%

Liquidity 50%

Performance 23%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-7.32%

1 Month

-11.07%

3 Months

-13.96%

6 Months

-0.22%

1 Year

15.90%

2 Year

-4.78%

Key data

Stock price

$27.48

P/E Ratio

0.00

DAY RANGE

$27.20 - $27.81

EPS

$1.33

52 WEEK RANGE

$17.24 - $35.43

52 WEEK CHANGE

$13.84

MARKET CAP

18.386 B

YIELD

N/A

SHARES OUTSTANDING

661.369 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

08-07-2025

BETA

0.33

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,632,656

AVERAGE 30 VOLUME

$1,731,564

Company detail

CEO: Jan G. J. van de Winkel
Region: US
Website: genmab.com
Employees: 1,660
IPO year: 2009

Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases. The company markets DARZALEX, a human monoclonal antibody for the. treatment of patients with multiple myeloma (MM) and ofatumurnab for. multiple sclerosis (CLL) and multiple sclerosis. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers.

GMAB - GENMAB A/S